



Sanofi Establishes a Global Agreement with Medco and UBC to Improve Quality of Patient Care through Real-World Evidence

- Goal is to better define relative value for products early in development and deliver integrated solutions for patients -

Paris, France - June 22, 2011 - Sanofi (EURONEXT: SAN and NYSE: SNY) announced today that it has entered into a global agreement with *Medco Health Solutions, Inc.* (NYSE: MHS) (Medco), and *United BioSource Corporation* (UBC), a wholly owned subsidiary of Medco, to better leverage the real-world evidence generated during product development and throughout the product lifecycle in order to improve the overall quality of patient care.

Medco and UBC hold a unique set of complementary capabilities in the areas of real-world evidence generation, personalized medicine and pharmacogenomics; research, safety and comparative effectiveness analytics; and clinical and adherence support.

Under the terms of this multi-year agreement, Medco and UBC will provide real-world input and comparative data into product development strategy. This agreement will allow Sanofi to define the relative value for products early in development, by more precisely identifying patient populations in which drugs are most effective. It will also enable Sanofi to maximize the full value potential of R&D innovation through early alignment of patient population assessments, payer and medical needs. The objective is to develop integrated solutions for patients by implementing novel care models and to improve adherence and patient outcomes.

"Medco and UBC offer a robust capability to help us close the gap between fundamental research and real world clinical setting and bring the transformative change to the drug development process required to improve the quality of patient care, while effectively meeting payer and other stakeholder evidence requirements," said Jean-Pierre Lehner, Chief Medical Officer of Sanofi. *"Through this agreement, we will make the leap from discovering and marketing new medicines to providing comprehensive healthcare solutions that are proven to drive safety, effectiveness and value for our stakeholders."*

"Some products, that seemed to hold promise in early research, might not deliver the intended results when used in real-world practice", said Dr. Rob Epstein, Medco President Advanced Clinical Science and Research and Chief Clinical Research and Development Officer. *"In the framework of this agreement real-world data will be used to develop products that demonstrate value in real-world settings, enabling Sanofi to support high quality, cost effective care,"*



About Medco

Medco Health Solutions, Inc. (NYSE: MHS) is pioneering the *world's most advanced pharmacy*[®] and its clinical research and innovations are part of *Medco making medicine smarter*[™] for approximately 65 million members.

With more than 20,000 employees worldwide dedicated to improving patient health and reducing costs for a wide range of public and private sector clients, and 2010 revenue of nearly \$66 billion, Medco ranks 35th on the 2010 *Fortune* 500 list and is named among the world's most innovative, most admired and most trustworthy companies. For more information, go to www.medcohealth.com.

About United BioSource Corporation

United BioSource Corporation (UBC), a wholly owned subsidiary of Medco Health Solutions, Inc. (NYSE: MHS), is a global scientific and medical affairs organization that partners with life science companies to make medicine and medical products smarter for all stakeholders in the health care landscape. We help deliver authoritative, real-world evidence to characterize product effectiveness, address safety risk, and demonstrate value. UBC brings together recognized scientific and industry experts, research operations professionals, and new technologies to provide innovative solutions across the product lifecycle. The company is headquartered in Bethesda, Maryland, with offices in North and South America, Europe and Asia. For more information about UBC, visit www.unitedbiosource.com.

About Sanofi

Sanofi, a global and diversified healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients' needs. Sanofi has core strengths in the field of healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, rare diseases, consumer healthcare, emerging markets and animal health. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).

Forward Looking Statements

This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements are generally identified by the words "expects", "anticipates", "believes", "intends", "estimates", "plans" and similar expressions. Although Sanofi's management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of such products candidates, the absence of guarantee that the products candidates if approved will be commercially successful, the future approval and commercial success of therapeutic alternatives, the Group's ability to benefit from external growth opportunities as well as those discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under "Risk Factors" and "Cautionary Statement Regarding Forward-Looking Statements" in Sanofi's annual report on Form 20-F for the year ended December 31, 2010. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements.

Contacts:

Media Relations

Jean-Marc Podvin
Tel.: + (33) 1 53 77 46 46
mr@sanofi.com

Investor Relations

Sébastien Martel
Tel.: + (33) 1 53 77 45 45
ir@sanofi.com